IP Library Granted Patent US 9,453,071
Granted Patent B2
US 9,453,071 · App. 11/920,160 · Granted Sep 27, 2016

Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,453,071
App. No.
11/920,160
Granted
Sep 27, 2016
Kind
B2
Abstract

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PlGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Claims (21)

1. An isolated hybridoma cell line, wherein the hybridoma cell line is deposited under Deposit Accession No. DSM ACC2774.

2. An isolated antibody wherein the antibody is monoclonal antibody 05-121/06, which is produced by a hybridoma cell line deposited under Deposit Accession No. DSM ACC2774.

3. An isolated antibody fragment of the antibody of claim 2 , wherein the antibody fragment specifically binds to a peptide consisting of the amino acid sequence VVPFQEVWGRSY (SEQ ID NO: 11).

4. A binding assay for detection of human Placental Growth Factor (PlGF) not bound by Fit-1 receptor (free PlGF) in a sample, comprising the steps of:

(a) bringing the antibody of claim 2 , the antibody fragment of claim 3 , or both, into contact with the sample,

(b) determining a binding complex comprising free PlGF from the sample and the antibody and/or the antibody fragment qualitatively or quantitatively.

5. A test kit for implementation of a binding assay for detection of human Placental Growth Factor (PlGF) not bound by Fit-1 receptor (free PlGF) in a sample, wherein the test kit comprises the antibody of claim 2 , the antibody fragment of claim 3 , or both, and reagents for detecting formation of a binding complex comprising free PlGF bound to the antibody and/or the antibody fragment.

6. An isolated hybridoma cell line, wherein the hybridoma cell line is deposited under Deposit Accession No. DSM ACC2775.

7. An isolated antibody, wherein the antibody is monoclonal antibody 05-120/03, which is produced by a hybridoma cell line deposited under Deposit Accession No. DSM ACC2775.

8. An isolated antibody fragment of the antibody of claim 7 , wherein the antibody fragment specifically binds to a peptide consisting of the amino acid sequence VVPFQEVWGRSY (SEQ ID NO: 11).

9. A binding assay for detection of human Placental Growth Factor (PlGF) not bound by Fit-1 receptor (free PlGF) in a sample, comprising the steps of:

(a) bringing the antibody of claim 7 , the antibody fragment of claim 8 , or both, into contact with the sample,

(b) determining a binding complex comprising free PlGF from the sample and the antibody and/or the antibody fragment qualitatively or quantitatively.

10. A test kit for implementation of a binding assay for detection of human Placental Growth Factor (PlGF) not bound by Flt-1 receptor (free PlGF) in a sample, wherein the test kit comprises the antibody of claim 7 , the antibody fragment of claim 8 , or both, and reagents for detecting formation of a binding complex comprising free PlGF bound to the antibody and/or the antibody fragment.

11. An isolated peptide consisting of the amino acid sequence VVPFQEVWGRSY (SEQ ID NO: 11), wherein the peptide is coupled to a carrier protein selected from the group consisting of ovalbumin, albumin, and keyhole limpet hemocyanin.

12. A process for preparation of an antibody which specifically binds free human Placental Growth Factor (PlGF) but not human PlGF bound by Flt-1 receptor, the process comprising the steps of:

(a) immunizing an experimental animal with the carrier-coupled peptide of claim 11 ,

(b) fusing spleen cells of the immunized experimental animal with myeloma cells, whereby antibody-producing hybrid cells are formed,

(c) cloning the hybrid cells,

(d) selecting a hybrid cell clone which produces an antibody which selectively binds to a peptide consisting of the amino acid sequence VVPFQEVWGRSY (SEQ ID NO: 11), and

(e) isolating antibodies from the hybrid cell clone thus selected.

Assignments (2)
CHANGE OF NAME Recorded Feb 26, 2009
From: DADE BEHRING MARBURG GMBH
To: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
Reel/Frame 022309/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2007
From: VITZHUM, FRANK; TEIGELKAMP, STEFAN; ALTHAUS, HARALD
To: DADE BEHRING MARBURG GMBH
Reel/Frame 020148/0269 →